<DOC>
	<DOCNO>NCT00683514</DOCNO>
	<brief_summary>This multicenter , open-label , randomise , phase III study 2 cycle oral vinorelbine combination cisplatin concurrently radiotherapy randomise either two cycle consolidation therapy oral vinorelbine cisplatin plus Best Supportive Care ( BSC ) BSC alone patient unresectable locally advanced non small cell lung cancer ( NSCLC ) . The primary objective compare progression-free survival arm , secondary evaluate response rate , overall survival arm , evaluate safety profile arm assess quality life LCSS questionnaire .</brief_summary>
	<brief_title>Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Main Presence least one measurable lesion ( RECIST criterion ) Patients Karnofsky Performance Status = &gt; 80 % Adequate pulmonary function , bone marrow , hepatic renal function Main Patients NSCLC stage IV , NSCLC stag I , II , IIIA ( except N2 ) , NSCLC stage IIIB tumour extent pleural effusion Symptomatic neuropathy &gt; Grade 1 Hearing impairment = &gt; Grade 2 Concomitant/uncontrolled medical disorder Pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Untreated locally advanced inoperable stage IIIA stage IIIB NSCLC amenable radical radiotherapy dose 66 Gy</keyword>
</DOC>